Compare Incyte Corporation (INCY) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Advanced Drainage Systems Inc — how do they compare? Incyte Corporation trades at $117.86 (market cap $23.11B), while Advanced Drainage Systems Inc trades at $139.58 (market cap $10.96B). The key difference: Incyte Corporation is far larger — about 2.1× Advanced Drainage Systems Inc's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WMS | |
|---|---|---|
Market Cap | $23.11B | $10.96B |
Sector | Health | Industrials |
52-Week High | $118.52 | $175.38 |
52-Week Low | $67.38 | $110.99 |
Enterprise Value | $19.13B | $12.53B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
WMS trades at $142.93, down 3.13% today, with a neutral technical signal and mixed analyst sentiment. The company shows strong profitability with a 13.98% net income margin and 24.02% ROE, though revenue remained flat at $2.90B in 2025. Recent earnings beats and a dividend increase signal management confidence, while cash flow turned negative due to increased investing activities.
The outlook is cautiously optimistic with a consensus price target of $184.43 offering 29% upside. Risks include volatile cash flows and competitive pressures, but consistent earnings outperformance and solid balance sheet strength support a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
